Neogenomics
The company's Q4 revenues grew 10 percent and full-year revenues increased 5 percent, exceeding analysts' average estimates.
Data from an early-phase trial has spurred the firm to validate its blood-based residual disease assay, Radar, in neoadjuvant bladder cancer.
Natera Files Second Patent Infringement Suit Against NeoGenomics Subsidiary Inivata
The suit was filed the same day Natera received a new patent covering its patient-specific residual cancer testing and monitoring methods.
The company has faced some early hurdles in joining competitors in the colorectal cancer space but believes it can claim first mover status in early breast cancer.
360Dx Top 30 Grows 8 Percent, Continues Upward Climb
Of the 30 companies in the index, 21 saw their stock prices rise, while nine firms' share prices decreased.
Nov 8, 2022
Aug 9, 2022
Apr 1, 2022
360Dx Top 30 Falls Slightly in March
Feb 17, 2022
Nov 4, 2021
Nov 4, 2021
NeoGenomics Q3 Revenues Drop 3 Percent
Aug 6, 2021
NeoGenomics Q2 Revenues Grow 40 Percent
May 7, 2021